Inventor · disambiguated record
Devin Mcdougald
Also filed as: MCDOUGALD DEVIN
2 granted patents·15 pending applications·2 citations·filing 2018–2025
38Inventor score
Top patents by PatentIndex Score
17 records- 0176US11879133B2Gene therapy for ocular disordersUNIV PENNSYLVANIA·Filed 2018·Granted Jan 23, 2024·2 cites·21 claims
- 0276US2025367326A1Microdystrophin nucleic acid gene therapy constructs and uses thereofREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0376US2025367328A1Methods of manufacturing microdystrophin gene therapy constructsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0476US2025367327A1Treatment of dystrophinopathies with microdystrophin gene therapy constructsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0567US2024218394A1Gene therapy for ocular disordersUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 0663US2023270886A1Microdystrophin gene therapy constructs and uses thereofREGENXBIO INC·Filed 2020·Application pending·0 cites
- 0760US2025213727A1Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapyREGENXBIO INC·Filed 2023·Application pending·0 cites
- 0860US2025288697A1Vectorized anti-tnf-alpha inhibitors for ocular indicationsREGENXBIO INC·Filed 2023·Application pending·0 cites
- 0956US2024384292A1Vectorized tnf-alpha antagonists for ocular indicationsREGENXBIO INC·Filed 2021·Application pending·0 cites
- 1056US2024309076A1Tau-specific antibody gene therapy compositions, methods and uses thereofREGENXBIO INC·Filed 2021·Application pending·0 cites
- 1152US2025326861A1Vectorized lanadelumab and administration thereofREGENXBIO INC·Filed 2021·Application pending·0 cites
- 1250US11793887B2Gene therapy for treating peroxisomal disordersUNIV PENNSYLVANIA·Filed 2018·Granted Oct 24, 2023·0 cites·21 claims
- 1350US2025025574A1Engineered nucleic acid regulatory elements and methods and uses thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 1450US2023391864A1Vectorized anti-tnf-alpha antibodies for ocular indicationsREGENXBIO INC·Filed 2021·Application pending·0 cites
- 1543US2023042103A1Engineered nucleic acid regulatory element and methods of uses thereofREGENXBIO INC·Filed 2020·Application pending·0 cites
- 1643US2022195462A1Fully-human post-translationally modified antibody therapeuticsREGENXBIO INC·Filed 2020·Application pending·0 cites
- 1740US2023064077A1Treatment of mucopolysaccharidosis ivaREGENXBIO INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Devin Mcdougald files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →